Author of

• 18502

  +

  P3.02c - Poster Session with Presenters Present (ID 472)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 18507

    +

    P3.02c-005 - MET Exon 14 Skipping in Quintuple-Negative (EGFR-/KRAS-/ALK-/ROS1-/RET-) Lung Adenocarcinoma (ID 6012)

    14:30 - 14:30  |  Author(s): D. Oh
    • Abstract

    Background:
    MET exon 14 (METex14) skipping has been reported as a potentially targetable driver mutation in lung adenocarcinoma. We aimed to evaluate the prevalence and clinicopathologic characteristics of lung adenocarcinoma harboring METex14 skipping in patients with lung adenocarcinoma in which targetable genomic alterations are not available.
    
    Methods:
    We screened 795 patients with lung adenocarcinoma and 45 patients with quintuple-negative (EGFR-/KRAS-/ALK-/ROS1-/RET-) lung adenocarcinomas were finally included to identify the patients harboring METex14 skipping by using RT-PCR with probes overlapping an exon 13–15 junction. In addition, we summarized recent articles reported about METex14 skipping in lung cancer.
    
    Results:
    Based on the present study, seventeen patients (37.8%) had tumors harboring METex14 skipping alterations. Diverse genomic sequence variants causing METex14 skipping were identified. The median age of the METex14 skipping-positive patients was 73 years (range, 55–81 years), 8 patients (47.1%) were female, and 7 (41.2%) had never smoked. The predominant subtype was acinar followed by the solid type. The MET immunohistochemistry test for METex14 skipping demonstrated 100% (95% CI, 79.6–100) sensitivity and 70.4% (95% CI, 51.5–84.2) specificity. In literature reviews, we included 619 patients with lung cancer harboring METex14 skipping. The median age of the patients was 68 years (range, 41-84), 60% (251/418) were female, and 50% (58/116) were never smoker. MET immunochemical stain was positive in 62.3% (48/77), MET amplification was identified in 14.6% (45/309) of the patients. The prevalences of METex14 skipping were 12.9% (20/155) in sarcomatoid carcinoma, 3.9% (11/282) in adenosquamous carcinoma, 2.6% (398/15050) in adenocarcinoma, 2.1% (26/1226) in squamous cell carcinoma, and 0.8% (2/243) in large cell carcinoma, respectively.
    
    Conclusion:
    The prevalence of METex14 skipping was relatively high in patients with quintuple-negative (EGFR-/KRAS-/ALK-/ROS1-/RET-) lung adenocarcinomas. Lung adenocarcinomas harboring METex14 skipping were associated with old age, acinar or solid histolgy, and MET protein overexpression. Identification of subpopulation harboring METex14 skipping can be an important step toward developing targeted therapies for patients with lung cancer.